Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lintuzumab satetraxetan ac-225
- Development stage
- Phase 2
- Lead developer
- Actinium Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lintuzumab satetraxetan AC‑225 is a radioimmunoconjugate composed of the humanized anti-CD33 monoclonal antibody, lintuzumab, conjugated to the alpha-emitting radioisotope actinium‑225. This drug targets CD33, a cell surface antigen expressed on most acute myeloid leukemia (AML) cells and some other myeloid malignancies. Upon binding to CD33-positive cells, the attached actinium‑225 delivers potent alpha-particle radiation directly to malignant cells, causing double-stranded DNA breaks and cell death with minimal impact on surrounding healthy tissue due to the short path length of alpha emissions. Lintuzumab satetraxetan AC‑225 is being developed primarily for AML and high-risk myelodysplastic syndromes (MDS), with ongoing research in other cancers expressing CD33. The drug has orphan designation for AML and is under development by Actinium Pharmaceuticals in collaboration with several academic institutions[1][2][5][6][7].
- Brand names
- Actimab-A
- Other names
- Actimab-MDSActimab-M
02
Targets
CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on lintuzumab satetraxetan ac-225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lintuzumab satetraxetan ac-225.